I suspect they will wait and see how CLTX performs in the phase...

I suspect they will wait and see how CLTX performs in the phase 1 trial (maybe after an interim read-out in Q4) before they start a collaboration to do a combination therapy with something like a PD-L1 checkpoint inhibitor.

While PD-L1 checkpoint inhibitors are an FDA approved product (since 2017), I would think that it would be prudent to see at least some human trial data using CLTX before CHM or another party would agree to enter into a collaboration. For CHM, it will guide them as to what combination therapy would make sense (that is, does the data suggest a PD-L1 would work best, or maybe an IL-12 / IL -15 combination might work better?)

Which is why I think if the interim read-out in Q4 shows any sign of efficacy in such low doses, it could trigger some very interesting collaborations that may well enter the clinic next year and be well advanced should CLTX be approved by the FDA as opposed to waiting for FDA approval before starting new trials (time is of the essence).

Though the fact that Glioblastoma is such a devastating disease with no effective treatment at the moment, the FDA is more than likely going to approve a treatment that can increase survival and demonstrate progression free survival for patients suffering from Glioblastoma (who have an average survival of approx 6 months). If we ever heard the words complete response and no relapse in an announcement from CHM (not likely in low doses, but possibly in the latter stages of phase 1 early next year)... then mark my words, it will make global headlines.